However, it should be considered that patients enrolled in the EMPEROR-Preserved trial [76] had more comorbidities and lower EF and higher NT-proBNP levels compared to those in other HFpEF studies such as PARAGON-HF [77,78,79]. The gene discussed is NPPB; the disease is hydrops fetalis.